Contract for the supply of CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours
Prior information notice
Supplies
Section I: Contracting authority
I.1)Name, addresses and contact point(s)
University Hospitals Birmingham
Procurement, University Hospital Birmingham, 32-34 Melchett Road
For the attention of: Mr. Stephen Cross
B30 3HG Kings Norton
UNITED KINGDOM
Telephone: +44 1212041837
E-mail:
Fax: +44 1214590005
Internet address(es):
General address of the contracting authority: www.uhb.nhs.uk
Address of the buyer profile: www.uhb.nhs.uk
Further information can be obtained from: The above mentioned contact point(s)
I.2)Type of the contracting authority
Body governed by public law
I.3)Main activity
Health
I.4)Contract award on behalf of other contracting authorities
The contracting authority is purchasing on behalf of other contracting authorities: no
Section II.B: Object of the contract (Supplies or services)
II.1)Title attributed to the contract by the contracting authority:
Contract for the supply of CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours
II.2)Type of contract and place of delivery or of performance
Supplies
Birmingham.
Birmingham.
NUTS code UKG3
II.3)Information on framework agreement
II.4)Short description of nature and quantity or value of supplies or services:
University Hospitals Birmingham NHS Foundation Trust is calling for expressions of interest to this Prior Information Notice from suitably qualified suppliers CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours via the Trusts existing Rotagene and Pyrosequencing equipment.
This prior information notice is servicing three purposes:
1) To advise the market that the Trust will be tendering this project within the next 12 months.
2) To improve our knowledge of the market and its players and to have the opportunity to undertake early market engagement prior to the publication of the tender.
3) To undertake market testing before the publication of the tender documents
The Trust currently has a contract in place for the supply of reagents and consumables for PCR Analysis until 31.7.2014 and it is envisaged that a new contract arrangement for the supply of CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours via its , Rotagene and Pyrosequencing equipment will be commissioned by the 01/08/2014, using standard NHS Terms and conditions. The Trust's estimated annual spend across this portfolio is GBP 425,000 These products are used by the Histopathology department who are based within the Clinical Laboratories in division 4A of the Trusts structure.
The Trust will be keen to engage with the market prior to publishing the tender discuss the opportunities for streamlining the order process, discuss cost saving opportunities, lean process implementation and added value options.
We would request that all communication regarding this PIN publication is made either through the portal or via the Procurement department. No engagement should be made with the clinical staff at this point.
Please ensure that you only express an interest if you can genuinely provide suppliers CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours via the Trusts existing Rotagene and Pyrosequencing equipment. It is the intention that engagement will be made with registered supplied within the next 52 days. Suppliers should follow the additional instructions within the e-procurement portal once they have logged in to this opportunity.
Estimated cost excluding VAT:
Range: between 1 000 000 and 2 000 000 GBP
This prior information notice is servicing three purposes:
1) To advise the market that the Trust will be tendering this project within the next 12 months.
2) To improve our knowledge of the market and its players and to have the opportunity to undertake early market engagement prior to the publication of the tender.
3) To undertake market testing before the publication of the tender documents
The Trust currently has a contract in place for the supply of reagents and consumables for PCR Analysis until 31.7.2014 and it is envisaged that a new contract arrangement for the supply of CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours via its , Rotagene and Pyrosequencing equipment will be commissioned by the 01/08/2014, using standard NHS Terms and conditions. The Trust's estimated annual spend across this portfolio is GBP 425,000 These products are used by the Histopathology department who are based within the Clinical Laboratories in division 4A of the Trusts structure.
The Trust will be keen to engage with the market prior to publishing the tender discuss the opportunities for streamlining the order process, discuss cost saving opportunities, lean process implementation and added value options.
We would request that all communication regarding this PIN publication is made either through the portal or via the Procurement department. No engagement should be made with the clinical staff at this point.
Please ensure that you only express an interest if you can genuinely provide suppliers CE marked kits to undertake EGFR; IDH-1; KRAS; MGMT and NRAS testing for Mutation Analysis in Solid Tumours via the Trusts existing Rotagene and Pyrosequencing equipment. It is the intention that engagement will be made with registered supplied within the next 52 days. Suppliers should follow the additional instructions within the e-procurement portal once they have logged in to this opportunity.
Estimated cost excluding VAT:
Range: between 1 000 000 and 2 000 000 GBP
Lots
This contract is divided into lots: noII.5)Common procurement vocabulary (CPV)
33696500, 33696300, 33694000
II.6)Scheduled date for start of award procedures
II.7)Information about Government Procurement Agreement (GPA)
The contract is covered by the Government Procurement Agreement (GPA): yes
II.8)Additional information:
It is expected that the tender process will commence later this year.
Section III: Legal, economic, financial and technical information
III.1)Conditions relating to the contract
III.1.1)Main financing conditions and payment arrangements and/or reference to the relevant provisions governing them:
Will be publishing in tender suite of documents.
III.2)Conditions for participation
III.2.1)Information about reserved contracts
Section VI: Complementary information
VI.1)Information about European Union funds
VI.2)Additional information:
VI.3)Information on general regulatory framework
VI.4)Date of dispatch of this notice:
1.2.2014